

Kevin Garey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8169093/publications.pdf>

Version: 2024-02-01

300
papers

12,432
citations

50244

46
h-index

30058

103
g-index

308
all docs

308
docs citations

308
times ranked

10567
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, e1-e48.	2.9	1,695
2	Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi-Institutional Study. Clinical Infectious Diseases, 2006, 43, 25-31.	2.9	1,026
3	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, 987-994.	2.9	900
4	Interrupted Time Series Analysis of Vancomycin Compared to Cefuroxime for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery. Antimicrobial Agents and Chemotherapy, 2008, 52, 446-451.	1.4	524
5	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clinical Infectious Diseases, 2015, 60, 892-899.	2.9	369
6	Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. Journal of Hospital Infection, 2008, 70, 298-304.	1.4	340
7	Collection and Analysis of Exhaled Breath Condensate in Humans. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 731-737.	2.5	286
8	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clinical Infectious Diseases, 2021, 73, e1029-e1044.	2.9	270
9	Economic healthcare costs of Clostridium difficile infection: a systematic review. Journal of Hospital Infection, 2010, 74, 309-318.	1.4	264
10	A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2011, 66, 2850-2855.	1.3	154
11	FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia. Clinical Infectious Diseases, 2014, 59, 819-825.	2.9	147
12	Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2007, 51, 35-39.	1.4	144
13	Markers of Inflammation in Exhaled Breath Condensate of Young Healthy Smokers. Chest, 2004, 125, 22-26.	0.4	142
14	Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways. MBio, 2019, 10, .	1.8	141
15	Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes. Antimicrobial Agents and Chemotherapy, 2010, 54, 3717-3722.	1.4	138
16	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clinical Infectious Diseases, 2018, 66, 1678-1686.	2.9	129
17	Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. Clinical Microbiology Reviews, 2019, 33, .	5.7	129
18	Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 1160-1164.	1.4	122

#	ARTICLE	IF	CITATIONS
19	Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 645-650.	1.3	108
20	Outcomes of Bacteremia due to <i>Pseudomonas aeruginosa</i> with Reduced Susceptibility to Piperacillin-Tazobactam: Implications on the Appropriateness of the Resistance Breakpoint. <i>Clinical Infectious Diseases</i> , 2008, 46, 862-867.	2.9	106
21	Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of <i>Clostridioides difficile</i> Infection in Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 755-757.	2.9	105
22	Real-Time Polymerase Chain Reaction Detection of Asymptomatic <i>Clostridium difficile</i> Colonization and Rising <i>C. difficile</i> Associated Disease Rates. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 667-673.	1.0	101
23	Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 201-211.	2.0	99
24	Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of $\geq 1/4$ g/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. <i>Clinical Therapeutics</i> , 2006, 28, 1208-1216.	1.1	97
25	<i>Clostridium difficile</i> infection: update on emerging antibiotic treatment options and antibiotic resistance. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 555-564.	2.0	96
26	A Common Polymorphism in the Interleukin 8 Gene Promoter Is Associated with <i>Clostridium difficile</i> Diarrhea. <i>American Journal of Gastroenterology</i> , 2006, 101, 1112-1116.	0.2	91
27	Cytokines Are Markers of the <i>Clostridium difficile</i> -Induced Inflammatory Response and Predict Disease Severity. <i>Vaccine Journal</i> , 2017, 24, .	3.2	90
28	Echinocandin Resistance in <i>Candida</i> Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1086-1096.	0.9	87
29	Rifaximin in Treatment of Recurrent <i>Clostridium difficile</i> -associated Diarrhea: An Uncontrolled Pilot Study. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 91-92.	1.1	83
30	Human-Derived <i>Bifidobacterium dentium</i> Modulates the Mammalian Serotonergic System and Gut-Brain Axis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 221-248.	2.3	73
31	Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of <i>Candida</i> species using seeded blood samples. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 77, 324-326.	0.8	71
32	A clinical risk index for <i>Clostridium difficile</i> infection in hospitalised patients receiving broad-spectrum antibiotics. <i>Journal of Hospital Infection</i> , 2008, 70, 142-147.	1.4	70
33	Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 14, 58-64.	0.9	70
34	Comparative Toxicity and Concentrations of Intravitreal Amphotericin B Formulations in a Rabbit Model. , 2003, 44, 2112.		69
35	Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2146-2151.	1.3	67
36	Rifamycin Antibiotics for Treatment of <i>Clostridium difficile</i> -Associated Diarrhea. <i>Annals of Pharmacotherapy</i> , 2008, 42, 827-835.	0.9	65

#	ARTICLE	IF	CITATIONS
37	A Common Polymorphism in the Interleukin-8 Gene Promoter Is Associated with an Increased Risk for Recurrent Clostridium difficile Infection. <i>Clinical Infectious Diseases</i> , 2010, 51, 1406-1410.	2.9	64
38	Long-term Clarithromycin Decreases Prednisone Requirements in Elderly Patients With Prednisone-Dependent Asthma. <i>Chest</i> , 2000, 118, 1826-1827.	0.4	63
39	Tissue Reparative Effects of Macrolide Antibiotics in Chronic Inflammatory Sinopulmonary Diseases. <i>Chest</i> , 2003, 123, 261-265.	0.4	61
40	Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 919-927.	0.9	60
41	New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 500-507.	1.3	60
42	Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. <i>Journal of Hospital Infection</i> , 2016, 93, 286-289.	1.4	59
43	Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1245-1251.	1.3	54
44	Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. <i>Clinical Microbiology and Infection</i> , 2007, 13, 413-418.	2.8	52
45	Moderate to High Use of Opioid Analgesics Are Associated With an Increased Risk of Clostridium difficile Infection. <i>American Journal of the Medical Sciences</i> , 2012, 343, 277-280.	0.4	51
46	Investigation of potentially pathogenic Clostridium difficile contamination in household environs. <i>Anaerobe</i> , 2014, 27, 31-33.	1.0	50
47	Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer. <i>Nutrition in Clinical Practice</i> , 2016, 31, 171-179.	1.1	50
48	Treatment of Candida famata bloodstream infections: case series and review of the literature. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 438-443.	1.3	49
49	Economic health care costs of blood culture contamination: A systematic review. <i>American Journal of Infection Control</i> , 2019, 47, 963-967.	1.1	48
50	Association of Interleukin-8 Polymorphism and Immunoglobulin G Anti-Toxin A in Patients With Clostridium difficile-Associated Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 964-968.	2.4	47
51	A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. <i>PLoS ONE</i> , 2015, 10, e0123405.	1.1	47
52	A Prospective and Retrospective Analysis of the Nephrotoxicity and Efficacy of Lipid-Based Amphotericin B Formulations. <i>Pharmacotherapy</i> , 2001, 21, 1107-1114.	1.2	46
53	Impact of Prior Inappropriate Fluconazole Dosing on Isolation of Fluconazole-Nonsusceptible Candida Species in Hospitalized Patients with Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3239-3243.	1.4	46
54	Evaluation of Portability and Cost of a Fluorescent PCR Ribotyping Protocol for Clostridium difficile Epidemiology. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1192-1197.	1.8	46

#	ARTICLE	IF	CITATIONS
55	Fusobacterium nucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. Gastroenterology, 2021, 160, 1301-1314.e8.	0.6	46
56	Intravenous Azithromycin. Annals of Pharmacotherapy, 1999, 33, 218-228.	0.9	44
57	The importance of CD25+CD4+ regulatory T cells in mouse hepatic allograft tolerance. Liver Transplantation, 2006, 12, 1112-1118.	1.3	44
58	Community Environmental Contamination of Toxigenic Clostridium difficile. Open Forum Infectious Diseases, 2017, 4, ofx018.	0.4	44
59	Prevalence of Type III Secretion Protein Exoenzymes and Antimicrobial Susceptibility Patterns from Bloodstream Isolates of Patients with Pseudomonas aeruginosa Bacteremia. Journal of Chemotherapy, 2008, 20, 714-720.	0.7	42
60	Ridinilazole: a novel therapy for Clostridium difficile infection. International Journal of Antimicrobial Agents, 2016, 48, 137-143.	1.1	41
61	Prevalence of Diarrhea at a University Hospital and Association with Modifiable Risk Factors. Annals of Pharmacotherapy, 2006, 40, 1030-1034.	0.9	40
62	Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. Journal of Hospital Infection, 2007, 65, 42-46.	1.4	40
63	Crofelemer for the treatment of secretory diarrhea. Expert Review of Gastroenterology and Hepatology, 2012, 6, 17-23.	1.4	40
64	Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. Journal of Clinical Gastroenterology, 2016, 50, 631-637.	1.1	40
65	Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2007, 58, 309-314.	0.8	39
66	In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. Journal of Clinical Pathology, 2010, 63, 355-358.	1.0	39
67	Crofelemer, a Novel Agent for Treatment of Secretory Diarrhea. Annals of Pharmacotherapy, 2010, 44, 878-884.	0.9	39
68	Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 859-867.	1.3	39
69	Peripartum Clostridium difficile infection: case series and review of the literature. American Journal of Obstetrics and Gynecology, 2008, 199, 332-337.	0.7	38
70	In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infection Control and Hospital Epidemiology, 2015, 36, 1318-1323.	1.0	38
71	Effect of a Health Care System Respiratory Fluoroquinolone Restriction Program To Alter Utilization and Impact Rates of Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	37
72	Clinical Practice Patterns in Hospitalized Patients at Risk for Invasive Candidiasis. Annals of Pharmacotherapy, 2014, 48, 683-690.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa051.	0.4	36
74	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab371.	0.4	36
75	Future novel therapeutic agents for <i>Clostridium difficile</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 825-836.	1.9	35
76	Integrating gut microbiome and host immune markers to understand the pathogenesis of <i>Clostridioides difficile</i> infection. <i>Gut Microbes</i> , 2021, 13, 1-18.	4.3	35
77	Real-world Experience of Bezlotoxumab for Prevention of <i>Clostridioides difficile</i> Infection: A Retrospective Multicenter Cohort Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa097.	0.4	35
78	Trovafloxacin: An Overview. <i>Pharmacotherapy</i> , 1999, 19, 21-34.	1.2	34
79	High Horn's index score predicts poor outcomes in patients with <i>Clostridium difficile</i> infection. <i>Journal of Hospital Infection</i> , 2011, 79, 23-26.	1.4	34
80	Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. <i>Epidemiology and Infection</i> , 2016, 144, 189-197.	1.0	33
81	Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of <i>Clostridium difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2690-2693.	1.4	32
82	Identification of Toxemia in Patients with <i>Clostridium difficile</i> Infection. <i>PLoS ONE</i> , 2015, 10, e0124235.	1.1	32
83	<i>Cunninghamella bertholletiae</i> Infection in a Bone Marrow Transplant Patient: Amphotericin Lung Penetration, MIC Determinations, and Review of the Literature. <i>Pharmacotherapy</i> , 2001, 21, 855-860.	1.2	31
84	Economic Consequences of Unused Medications in Houston, Texas. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1165-1168.	0.9	31
85	Telithromycin: An Oral Ketolide for Respiratory Infections. <i>Pharmacotherapy</i> , 2001, 21, 1204-1222.	1.2	29
86	Involvement of Immunization-Certified Pharmacists with Immunization Activities. <i>Annals of Pharmacotherapy</i> , 2004, 38, 226-231.	0.9	29
87	Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 557-562.	1.1	29
88	Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 81, 4-8.	0.8	29
89	Association between health literacy and 30-day healthcare use after hospital discharge in the heart failure population. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 754-758.	1.5	29
90	Azathioprine Hypersensitivity Reaction in a Patient with Ulcerative Colitis. <i>Annals of Pharmacotherapy</i> , 1998, 32, 425-428.	0.9	28

#	ARTICLE	IF	CITATIONS
91	Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. <i>Mycoses</i> , 2006, 49, 226-231.	1.8	28
92	Infectious Diseases: Tolerance of Vancomycin for Surgical Prophylaxis in Patients Undergoing Cardiac Surgery and Incidence of Vancomycin-Resistant Enterococcus Colonization. <i>Annals of Pharmacotherapy</i> , 2006, 40, 381-385.	0.9	28
93	A Real-World Evaluation of Oral Vancomycin for Severe <i>Clostridium difficile</i> Infection: Implications for Antibiotic Stewardship Programs. <i>Pharmacotherapy</i> , 2012, 32, 129-134.	1.2	28
94	Pharmacist-Managed Vaccination Program Increased Influenza Vaccination Rates in Cardiovascular Patients Enrolled in a Secondary Prevention Lipid Clinic. <i>Pharmacotherapy</i> , 2007, 27, 729-733.	1.2	27
95	Increased rate of irritable bowel syndrome and functional gastrointestinal disorders after <i>Clostridium difficile</i> infection. <i>Journal of Hospital Infection</i> , 2011, 77, 172-173.	1.4	26
96	Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based <i>Clostridium difficile</i> infection treatment policy. <i>Journal of Hospital Infection</i> , 2013, 85, 28-32.	1.4	26
97	Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1204-1208.	0.5	26
98	Risk Factors for Vitamin D Deficiency in HIV-Infected Patients in the South Central United States. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 454-459.	0.5	25
99	Colonic Immunopathogenesis of <i>Clostridium difficile</i> Infections. <i>Vaccine Journal</i> , 2014, 21, 509-517.	3.2	25
100	Physician Attitudes Toward the Use of Fecal Transplantation for Recurrent <i>Clostridium difficile</i> Infection in a Metropolitan Area. <i>Clinical Infectious Diseases</i> , 2013, 56, 1059-1060.	2.9	24
101	Cadazolid for the treatment of <i>Clostridium difficile</i> . <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 509-514.	1.9	24
102	Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	24
103	Novel antibiotics in development to treat <i>Clostridium difficile</i> infection. <i>Current Opinion in Gastroenterology</i> , 2017, 33, 1-7.	1.0	24
104	Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of <i>Clostridium difficile</i> From Stool Samples. <i>Annals of Laboratory Medicine</i> , 2015, 35, 306-313.	1.2	23
105	Mechanisms for floor surfaces or environmental ground contamination to cause human infection: a systematic review. <i>Epidemiology and Infection</i> , 2017, 145, 347-357.	1.0	23
106	Human intestinal enteroids as a model of <i>Clostridioides difficile</i> -induced enteritis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G870-G888.	1.6	23
107	Lack of Effect of Zafirlukast on the Pharmacokinetics of Azithromycin, Clarithromycin, and 14-Hydroxycarithromycin in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1152-1155.	1.4	22
108	Inhibition of Biofilm Formation by Esomeprazole in <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4360-4364.	1.4	22

#	ARTICLE	IF	CITATIONS
109	Shoe soles as a potential vector for pathogen transmission: a systematic review. <i>Journal of Applied Microbiology</i> , 2016, 121, 1223-1231.	1.4	22
110	Healthcare Resource Utilization for Recurrent <i>Clostridium difficile</i> Infection in a Large University Hospital in Houston, Texas. <i>PLoS ONE</i> , 2014, 9, e102848.	1.1	21
111	PCR ribotypes of <i>Clostridioides difficile</i> across Texas from 2011 to 2018 including emergence of ribotype 255. <i>Emerging Microbes and Infections</i> , 2020, 9, 341-347.	3.0	21
112	Pharmacist intervention program for hospitalized patients with HIV infection. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 2283-2284.	0.5	20
113	Comparison of Risk Factors for Candidemia Versus Bacteremia in Hospitalized Patients. <i>Infection</i> , 2006, 34, 322-7.	2.3	20
114	<i>Clostridium difficile</i> -related death rates in Texas 1999–2005. <i>Journal of Infection</i> , 2009, 59, 303-307.	1.7	20
115	Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients. <i>Journal of Hospital Infection</i> , 2018, 98, 96-101.	1.4	20
116	<i>Clostridioides difficile</i> ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. <i>Anaerobe</i> , 2020, 62, 102142.	1.0	20
117	Cerebrospinal Fluid Concentrations of Quinupristin-Dalfopristin in a Patient with Vancomycin-Resistant <i>Enterococcus faecalis</i> Ventriculitis. <i>Pharmacotherapy</i> , 2001, 21, 748-750.	1.2	19
118	Improving patient care through implementation of an antimicrobial stewardship program. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 2170-2174.	0.5	19
119	The Integrity of Heme Is Essential for Reproducible Detection of Metronidazole-Resistant <i>Clostridioides difficile</i> by Agar Dilution Susceptibility Tests. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0058521.	1.8	19
120	Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study. <i>Current Therapeutic Research</i> , 2004, 65, 1-12.	0.5	18
121	A Blueprint for Transitioning Pharmacy Residents Into Successful Clinical Faculty Members in Colleges and Schools of Pharmacy. <i>American Journal of Pharmaceutical Education</i> , 2013, 77, 200.	0.7	18
122	Outcomes associated with <i>Clostridium difficile</i> infection in patients with chronic liver disease. <i>Epidemiology and Infection</i> , 2018, 146, 1101-1105.	1.0	18
123	<i>Clostridioides</i> (Formerly <i>Clostridium</i>) <i>difficile</i> Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. <i>Clinical Infectious Diseases</i> , 2019, 68, 1887-1893.	2.9	18
124	Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab365.	0.4	18
125	Mathematical Modeling To Characterize the Inoculum Effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4739-4743.	1.4	17
126	Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1471-1474.	0.5	17

#	ARTICLE	IF	CITATIONS
127	<i>In Vitro</i> Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. Journal of Clinical Microbiology, 2018, 56, .	1.8	17
128	Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent <i>Clostridium difficile</i> Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	17
129	Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with <i>Clostridioides difficile</i> Infection: A Phase 2a Multicenter Clinical Trial. Clinical Infectious Diseases, 2022, 75, 1164-1170.	2.9	17
130	Risk Factors for Postoperative Chest Wound Infections Due to Gram-negative Bacteria in Cardiac Surgery Patients. Journal of Chemotherapy, 2006, 18, 402-408.	0.7	16
131	Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection. Journal of Hospital Infection, 2013, 83, 294-299.	1.4	16
132	Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS. HIV/AIDS - Research and Palliative Care, 2013, 5, 153.	0.4	16
133	Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatric Blood and Cancer, 2015, 62, 80-84.	0.8	16
134	Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clinical Microbiology and Infection, 2018, 24, 1190-1194.	2.8	16
135	Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiology, 2019, 14, 1331-1341.	1.0	16
136	Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With <i>Clostridioides difficile</i> Infection. Clinical Infectious Diseases, 2022, 74, 2142-2149.	2.9	16
137	Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review. Antibiotics, 2022, 11, 258.	1.5	16
138	Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagnostic Microbiology and Infectious Disease, 2009, 63, 81-86.	0.8	15
139	Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagnostic Microbiology and Infectious Disease, 2009, 63, 279-285.	0.8	15
140	Education, Training, and Academic Experience of Newly Hired, First-Time Pharmacy Faculty Members. American Journal of Pharmaceutical Education, 2014, 78, 92.	0.7	15
141	Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs of Today, 2013, 49, 239.	0.7	15
142	High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Current Medical Research and Opinion, 2007, 23, 1057-1065.	0.9	14
143	Environmental transmission of <i>Clostridioides difficile</i> ribotype O27 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infection Control and Hospital Epidemiology, 2018, 39, 1322-1329.	1.0	14
144	Epidemic Clostridioides difficile Ribotype O27 Lineages: Comparisons of Texas Versus Worldwide Strains. Open Forum Infectious Diseases, 2019, 6, ofz013.	0.4	14

#	ARTICLE	IF	CITATIONS
145	<i>In Vitro</i> Activity of Omadacycline, a New Tetracycline Analog, and Comparators against <i>Clostridioides difficile</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	14
146	Significant publications on infectious diseases pharmacotherapy in 2009. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, e34-e42.	0.5	13
147	Bacterial colonization on writing pens touched by healthcare professionals and hospitalized patients with and without cleaning the pen with alcohol-based hand sanitizing agent. <i>Clinical Microbiology and Infection</i> , 2011, 17, 868-869.	2.8	13
148	A pilot study to assess bacterial and toxin reduction in patients with <i>Clostridium difficile</i> infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 22.	1.7	13
149	A systematic approach to optimize electronic health record medication alerts in a health system. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 530-536.	0.5	13
150	Activity of Hospital Disinfectants against Vegetative Cells and Spores of <i>Clostridioides difficile</i> Embedded in Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	13
151	Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With <i>Clostridioides difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz552.	0.4	13
152	The metabolic profile of <i>Bifidobacterium dentium</i> reflects its status as a human gut commensal. <i>BMC Microbiology</i> , 2021, 21, 154.	1.3	13
153	Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 81-82.	1.4	12
154	Evaluating the Effects of Surotomycin Treatment on <i>Clostridium difficile</i> Toxin A and B Production, Immune Response, and Morphological Changes. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3519-3523.	1.4	12
155	Characterization of <i>Clostridioides difficile</i> ribotypes in domestic dogs in Rio de Janeiro, Brazil. <i>Anaerobe</i> , 2019, 58, 22-29.	1.0	12
156	A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3635-3643.	1.3	12
157	Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa157.	0.4	12
158	Impact of <i>Clostridioides difficile</i> infection on patient-reported quality of life. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1339-1344.	1.0	12
159	Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. <i>Clinical Transplantation</i> , 2001, 15, 297-308.	0.8	11
160	Significant publications on infectious diseases pharmacotherapy in 2007. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, e72-e79.	0.5	11
161	Innate Inflammatory Response and Immunopharmacologic Activity of Micafungin, Caspofungin, and Voriconazole against Wild-Type and <i>FKS</i> Mutant <i>Candida glabrata</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5405-5412.	1.4	11
162	Age-Stratified Treatment Response Rates in Hospitalized Patients with <i>Clostridium difficile</i> Infection Treated with Metronidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6113-6116.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Accelerate PhenoTest TM BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. <i>Annals of Pharmacotherapy</i> , 2018, 52, 754-762.	0.9	11
164	Toxin A—Predominant Pathogenic <i>Clostridioides difficile</i> : A Novel Clinical Phenotype. <i>Clinical Infectious Diseases</i> , 2020, 70, 2628-2633.	2.9	11
165	Economic Benefit of Appropriate Timing of Vancomycin Prophylaxis in Patients Undergoing Cardiovascular Surgery. <i>Pharmacotherapy</i> , 2008, 28, 699-706.	1.2	10
166	Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 747-760.	2.0	10
167	A multi-center study of fidaxomicin use for <i>Clostridium difficile</i> infection. <i>SpringerPlus</i> , 2016, 5, 1224.	1.2	10
168	Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 568-572.	0.5	9
169	Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, S51-S57.	0.5	9
170	Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 41-47.	0.9	9
171	<i>Clostridioides difficile</i> Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2021, 72, e460-e465.	2.9	9
172	Pharmacists'™ perceptions of the effectiveness of antimicrobial control programs. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2504-2508.	0.5	8
173	Evaluation of a daptomycin dose-optimization protocol. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 979-984.	0.5	8
174	Fecal Calprotectin in the Diagnosis of <i>Clostridium difficile</i> Infection. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 31-34.	0.1	8
175	Bacteremia in Patients With Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 648-654.	1.1	8
176	Ridinilazole for the treatment of <i>Clostridioides difficile</i> infection. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 303-310.	1.9	8
177	Systems biology evaluation of refractory <i>Clostridioides difficile</i> infection including multiple failures of fecal microbiota transplantation. <i>Anaerobe</i> , 2021, 70, 102387.	1.0	8
178	Assessment of Kidney Injury as a Severity Criteria for <i>Clostridioides Difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa476.	0.4	8
179	Omadacycline and <i>Clostridioides difficile</i> : A Systematic Review of Preclinical and Clinical Evidence. <i>Annals of Pharmacotherapy</i> , 2023, 57, 184-192.	0.9	8
180	Bactericidal Activity and Postantibiotic Effect of Levofloxacin against Anaerobes. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2547-2549.	1.4	7

#	ARTICLE	IF	CITATIONS
181	An integrated pharmaco-economic approach to antimicrobial formulary decision-making. American Journal of Health-System Pharmacy, 2006, 63, 735-739.	0.5	7
182	Timing of fluconazole therapy and mortality in patients with Candidemia. American Journal of Infection Control, 2008, 36, S174.	1.1	7
183	Echinocandin Use in Hospitalized Patients: A Multi-institutional Study. American Journal of the Medical Sciences, 2015, 349, 316-320.	0.4	7
184	A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe, 2016, 40, 10-14.	1.0	7
185	In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. Journal of Antimicrobial Chemotherapy, 2020, 75, 2879-2884.	1.3	7
186	A survey to assess experiences and social support of underrepresented minority doctor of pharmacy students. Currents in Pharmacy Teaching and Learning, 2021, 13, 245-254.	0.4	7
187	Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe, 2021, 69, 102352.	1.0	7
188	Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students'™ Intention to Attend Lectures. American Journal of Pharmaceutical Education, 2020, 84, 7550.	0.7	7
189	Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. Journal of Patient-Reported Outcomes, 2022, 6, 49.	0.9	7
190	Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital. International Journal of Clinical Pharmacy, 2009, 31, 565-571.	1.4	6
191	Impact of a pharmacotherapy alerting system on medication errors. American Journal of Health-System Pharmacy, 2013, 70, 48-52.	0.5	6
192	Investigating inpatient medication administration using the theory of planned behavior. American Journal of Health-System Pharmacy, 2017, 74, 2065-2070.	0.5	6
193	Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe, 2019, 56, 88-90.	1.0	6
194	A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microbial Genomics, 2021, 7, .	1.0	6
195	Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use. Open Forum Infectious Diseases, 2021, 8, ofab419.	0.4	6
196	Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 028-038.	0.8	6
197	A Vancomycin HPLC Assay for Use in Gut Microbiome Research. Microbiology Spectrum, 2022, 10, e0168821.	1.2	6
198	Chlamydia pneumoniae, Clarithromycin, and Severe Asthma. Chest, 2001, 120, 1035-1036.	0.4	5

#	ARTICLE	IF	CITATIONS
199	Host Factors and Clinical Outcomes of Candida Colonization in Critically Ill Patients. <i>Mycopathologia</i> , 2015, 179, 87-93.	1.3	5
200	Molecular epidemiology of <i>Clostridioides difficile</i> in domestic dogs and zoo animals. <i>Anaerobe</i> , 2019, 59, 107-111.	1.0	5
201	Perils, Pitfalls, and Promise of Primary Prophylaxis for <i>Clostridioides difficile</i> Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1140-1141.	2.9	5
202	Complete Genome Sequence of <i>Clostridioides difficile</i> Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing. <i>Microbiology Resource Announcements</i> , 2019, 8, .	0.3	5
203	Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in <i>Clostridioides difficile</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
204	<i>Clostridium difficile</i> infection: an emerging epidemic with more questions than answers. <i>Future Microbiology</i> , 2010, 5, 1153-1156.	1.0	4
205	Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1053-1057.	0.5	4
206	Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 403-408.	0.9	4
207	Comparative clinical outcomes evaluation of hospitalized patients infected with <i>Clostridioides difficile</i> ribotype 106 vs. other toxigenic strains. <i>Anaerobe</i> , 2021, 72, 102440.	1.0	4
208	Higher In Vivo Fecal Concentrations of <i>Clostridioides difficile</i> Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection. <i>Clinical Infectious Diseases</i> , 2022, 75, 2019-2022.	2.9	4
209	Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent <i>Clostridioides difficile</i> Infection in ECOSPOR III, a Phase 3 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e1195-e1201.	2.9	4
210	Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 59-61.	0.8	3
211	The Role of Matching in Epidemiologic Studies. <i>American Journal of Pharmaceutical Education</i> , 2004, 68, 83.	0.7	3
212	Killing Activity of Rifampin with Piperacillin Therapy against Adherent Cells of <i>Pseudomonas aeruginosa</i> . <i>Journal of Chemotherapy</i> , 2008, 20, 652-654.	0.7	3
213	Reply to Bauer and Goff. <i>Clinical Infectious Diseases</i> , 2015, 61, 487-488.	2.9	3
214	Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area. <i>Journal of Pharmacy Practice</i> , 2016, 29, 188-193.	0.5	3
215	1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 <i>Clostridium difficile</i> (CD) Clinical Isolates and Impact of RDZ on Cell Morphology. <i>Open Forum Infectious Diseases</i> , 2018, 5, S419-S419.	0.4	3
216	Reply to Fabre et al. <i>Clinical Infectious Diseases</i> , 2018, 67, 1958-1959.	2.9	3

#	ARTICLE	IF	CITATIONS
217	Molecular epidemiology of toxigenic <i>Clostridioides difficile</i> isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. <i>Anaerobe</i> , 2020, 61, 102081.	1.0	3
218	Absence of Toxemia in <i>Clostridioides difficile</i> Infection: Results from Ultrasensitive Toxin Assay of Serum. <i>Digestive Diseases and Sciences</i> , 2020, 66, 3303-3306.	1.1	3
219	OUP accepted manuscript. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, S52-S57.	0.6	3
220	Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. <i>Current HIV Research</i> , 2021, 19, 61-72.	0.2	3
221	Humoral Immune Response to <i>Clostridioides difficile</i> Toxins A and B in Hospitalized Immunocompromised Patients With <i>C. difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab286.	0.4	3
222	Multi-country surveillance of <i>Clostridioides difficile</i> demonstrates high prevalence of spores in non-healthcare environmental settings. <i>Anaerobe</i> , 2022, 75, 102543.	1.0	3
223	Automated system to identify <i>Clostridium difficile</i> infection among hospitalised patients. <i>Journal of Hospital Infection</i> , 2009, 72, 337-341.	1.4	2
224	Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant <i>Candida</i> Species. <i>Current Fungal Infection Reports</i> , 2013, 7, 119-125.	0.9	2
225	Efficacy of Bezlotoxumab in Patients Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of <i>Clostridium difficile</i> Infection (CDI). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	2
226	Benchmarking and medication error rates. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 746-747.	0.5	2
227	Impact of New Diagnostic Approaches for Invasive Candidiasis on Antifungal Stewardship. <i>Current Fungal Infection Reports</i> , 2016, 10, 68-77.	0.9	2
228	Evaluating pharmacy leader development through the seven action logics. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 82-85.	0.5	2
229	A Protocol to Characterize the Morphological Changes of <i>Clostridium difficile</i> in Response to Antibiotic Treatment. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	2
230	688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S312-S313.	0.4	2
231	Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	2
232	Program development of a preceptor bootcamp for operational pharmacy preceptors. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, S2-S7.	0.5	2
233	Recent developments in antimicrobial therapy for gastrointestinal infections. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 30-36.	1.0	2
234	Stool Toxin Concentration Does Not Distinguish <i>Clostridioides difficile</i> Infection from Colonization in Children Less Than 3 Years of Age. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 454-458.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Chlamydia pneumoniae, Clarithromycin, and Severe Asthma. Chest, 2001, 120, 1036.	0.4	1
236	Is Asthma an Infectious Disease?. Clinical Pulmonary Medicine, 2001, 8, 117-122.	0.3	1
237	Pilot of a patient-centered pharmacy practice model. American Journal of Health-System Pharmacy, 2012, 69, 1860-1861.	0.5	1
238	Development And Validation Of The Promis Network To Evaluate Patient-Reported Health Status Associated With Clostridium Difficile Infection. Value in Health, 2015, 18, A27.	0.1	1
239	2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam. Open Forum Infectious Diseases, 2019, 6, S768-S769.	0.4	1
240	2378. Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients. Open Forum Infectious Diseases, 2019, 6, S820-S820.	0.4	1
241	2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations. Open Forum Infectious Diseases, 2019, 6, S896-S896.	0.4	1
242	668. Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared with Vancomycin (VAN). Open Forum Infectious Diseases, 2019, 6, S306-S306.	0.4	1
243	New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opinion in Internal Medicine, 2008, 7, 591-598.	1.5	1
244	Pathophysiology of C. difficile Infection. American Journal of Gastroenterology, 2013, 108, S169.	0.2	1
245	1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile. Open Forum Infectious Diseases, 2021, 8, S617-S617.	0.4	1
246	Colitis caused by Clostridioides difficile infection in a domestic dog: A case report. Anaerobe, 2022, 73, 102511.	1.0	1
247	The Role of Virus and Atypical Bacteria in the Pathogenesis of Asthma. Infectious Diseases in Clinical Practice, 2002, 11, 9-15.	0.1	0
248	INI COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED PATIENTS. Value in Health, 2005, 8, 243.	0.1	0
249	CV6 RISK FACTORS AND OUTCOMES OF SURGICAL SITE INFECTIONS IN DIABETICS UNDERGOING CARDIAC SURGERY. Value in Health, 2005, 8, 253.	0.1	0
250	PIN2 EFFECT OF INAPPROPRIATE ANTIBIOTIC THERAPY ON CLINICAL OUTCOMES OF PATIENTS WITH PSEUDOMONAS AERUGINOSA BACTEREMIA. Value in Health, 2005, 8, 305.	0.1	0
251	PIN4 IMPACT OF EMPIRIC ANTIFUNGAL THERAPY ON MORTALITY IN HOSPITALIZED PATIENTS WITH BLOODSTREAM CANDIDEMIA. Value in Health, 2005, 8, 305-306.	0.1	0
252	PIN23 ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER. Value in Health, 2005, 8, 311.	0.1	0

#	ARTICLE	IF	CITATIONS
253	PGI1 PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A LARGE TERTIARY CARE MEDICAL CENTER. Value in Health, 2005, 8, 369-370.	0.1	0
254	Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimization strategies. Current Infectious Disease Reports, 2008, 10, 9-13.	1.3	0
255	136. Critical Care Medicine, 2013, 41, A28.	0.4	0
256	1673 Microbial and Inflammatory Markers for Fatal Clostridium difficile Associated Diarrhea. Open Forum Infectious Diseases, 2014, 1, S447-S447.	0.4	0
257	COST BURDEN OF INAPPROPRIATE PROTON-PUMP INHIBITOR USE AMONG GASTROESOPHAGEAL REFLUX DISEASE PATIENTS. Value in Health, 2016, 19, A314.	0.1	0
258	Ribotypes Matter, Significance of Clostridium difficile Ribotypes in Cancer Patients with Diarrhea. Open Forum Infectious Diseases, 2017, 4, S386-S387.	0.4	0
259	First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh. Open Forum Infectious Diseases, 2017, 4, S406-S406.	0.4	0
260	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. Open Forum Infectious Diseases, 2017, 4, S52-S52.	0.4	0
261	471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh. Open Forum Infectious Diseases, 2018, 5, S176-S176.	0.4	0
262	1841. Implementation of an Outpatient Antimicrobial Stewardship Program to Reduce Fluoroquinolone Overprescribing at a Veterans Affairs Medical Center (VAMC). Open Forum Infectious Diseases, 2018, 5, S525-S525.	0.4	0
263	240. Estimated Clinical and Economic Impact Through Use of an Initial Specimen Diversion Device to Reduce Blood Culture Contamination: A Cost-benefit Analysis. Open Forum Infectious Diseases, 2018, 5, S102-S103.	0.4	0
264	501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers. Open Forum Infectious Diseases, 2018, 5, S186-S186.	0.4	0
265	510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals. Open Forum Infectious Diseases, 2018, 5, S189-S189.	0.4	0
266	2380. Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile. Open Forum Infectious Diseases, 2019, 6, S821-S822.	0.4	0
267	2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection. Open Forum Infectious Diseases, 2019, 6, S825-S825.	0.4	0
268	2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes. Open Forum Infectious Diseases, 2019, 6, S828-S828.	0.4	0
269	2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital. Open Forum Infectious Diseases, 2019, 6, S832-S832.	0.4	0
270	2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis. Open Forum Infectious Diseases, 2019, 6, S896-S897.	0.4	0

#	ARTICLE	IF	CITATIONS
271	1038. Impact of an Electronic Antibiotic Timeout on the Utilization of Frequently Prescribed Antibiotics in Hospitalized Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S365-S365.	0.4	0
272	2402. Clinical Outcomes Associated with an Emerging <i>Clostridioides difficile</i> Ribotype 255 in Texas. <i>Open Forum Infectious Diseases</i> , 2019, 6, S829-S829.	0.4	0
273	840. Clinical Failure Rates Associated with Hemin-induced Metronidazole Resistance in <i>Clostridioides difficile</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S11-S11.	0.4	0
274	2682. Prophylaxis-Driven Molecular Epidemiology of <i>Pseudomonas aeruginosa</i> Bloodstream Infections in Adults With Leukemia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S942-S942.	0.4	0
275	2235. Fecal Biomarkers for <i>Clostridioides difficile</i> Infection in Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S763-S764.	0.4	0
276	2382. Recurrent <i>Clostridioides difficile</i> Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life. <i>Open Forum Infectious Diseases</i> , 2019, 6, S822-S822.	0.4	0
277	2388. High-risk antibiotics associated with <i>Clostridioides difficile</i> infection: a national, multicenter analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, S825-S825.	0.4	0
278	Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 279-287.	0.4	0
279	Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, 174-180.	0.7	0
280	Systemization of a pharmacy technician career ladder in a multi-hospital system. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 2, 100036.	0.6	0
281	Overview of <i>Clostridium difficile</i> Infection as an Emerging Health Care Facility–Acquired Infection. <i>Hospital Pharmacy</i> , 2013, 48, S1-S6.	0.4	0
282	Fecal Calprotectin as a Biomarker for <i>Clostridium Difficile</i> Infection. <i>American Journal of Gastroenterology</i> , 2016, 111, S67.	0.2	0
283	RISEC: Rotational Invariant Segmentation of Elongated Cells in SEM Images with Inhomogeneous Illumination. <i>Lecture Notes in Computer Science</i> , 2019, , 553-563.	1.0	0
284	195. Antimicrobial Stewardship Incorporating New Antimicrobials for Use against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis. <i>Open Forum Infectious Diseases</i> , 2020, 7, S102-S102.	0.4	0
285	798. Metronidazole Exposure Prior to <i>Clostridioides difficile</i> Infection (CDI) is a Risk Factor for Severe <i>C. difficile</i> Disease in Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2020, 7, S442-S443.	0.4	0
286	1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S786-S786.	0.4	0
287	1197. Inhibitory Effect of Ursodeoxycholic Acid on <i>Clostridioides difficile</i> Growth. <i>Open Forum Infectious Diseases</i> , 2020, 7, S621-S621.	0.4	0
288	784. A Novel Method to Assess Virulence of <i>Clostridioides difficile</i> : Focus on <i>C. difficile</i> Ribotype 106. <i>Open Forum Infectious Diseases</i> , 2020, 7, S436-S437.	0.4	0

#	ARTICLE	IF	CITATIONS
289	787. Evaluation of <i>Clostridioides difficile</i> Environmental Contamination Surrounding <i>C. difficile</i> Patients vs. non- <i>C. difficile</i> Patients in Outpatient Infusion Centers. Open Forum Infectious Diseases, 2020, 7, S438-S438.	0.4	0
290	802. Proton Pump Inhibitors Increase <i>Clostridioides difficile</i> Disease Severity Controlling for Infecting Strains. Open Forum Infectious Diseases, 2020, 7, S444-S444.	0.4	0
291	795. Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Guideline on the Classification of <i>Clostridioides difficile</i> Infection Severity. Open Forum Infectious Diseases, 2020, 7, S441-S441.	0.4	0
292	825. An Academic-Information Technology Partnership to Create an Infectious Diseases Translational Science Database. Open Forum Infectious Diseases, 2020, 7, S454-S455.	0.4	0
293	645. Absence of Toxemia in <i>Clostridioides difficile</i> infection: Results from Ultrasensitive Toxin Assay of Serum. Open Forum Infectious Diseases, 2020, 7, S381-S382.	0.4	0
294	43. A Pharmacoepidemiologic Evaluation of Echinocandin Use. Open Forum Infectious Diseases, 2020, 7, S45-S45.	0.4	0
295	Genomic Epidemiology of <i>Clostridioides difficile</i> Sequence Types 1 and 2 Across Three US Medical Centers. Infection Control and Hospital Epidemiology, 2020, 41, s238-s238.	1.0	0
296	157. A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins. Open Forum Infectious Diseases, 2021, 8, S189-S190.	0.4	0
297	19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent <i>Clostridioides difficile</i> Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial. Open Forum Infectious Diseases, 2021, 8, S13-S13.	0.4	0
298	701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with <i>Clostridioides difficile</i> Infection. Open Forum Infectious Diseases, 2021, 8, S451-S451.	0.4	0
299	18. Global Surveillance of <i>Clostridioides difficile</i> Demonstrates High Prevalence in Non-Healthcare Settings. Open Forum Infectious Diseases, 2021, 8, S12-S13.	0.4	0
300	338. Multicenter Evaluation of Superinfection Occurrence and Impact on Clinical Outcomes in Patients with COVID-19. Open Forum Infectious Diseases, 2021, 8, S273-S274.	0.4	0